Skip to content

Microneedling with Fluorouracil in Patients with Stable Vitiligo

Efficacy of Topical Fluorouracil vs Microneedling with Fluorouracil in Patients with Stable Vitiligo

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221105056407N2
Enrollment
30
Registered
2024-04-20
Start date
2024-03-20
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo. Vitiligo

Interventions

Intervention 1: Control group: topical 5-Fluorouracil. In the 5-FU topical treatment group, patients will use 5-Fluorouracil topically on the lesions twice daily. The medicine will be in topical form

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: No new lesions and no progression of existing lesions for at least 2 years

Exclusion criteria

Exclusion criteria: pregnancy allergy to 5- Fluorouracil Patients with infectious patches, vitiligo spots on the mucous membrane, Kubner's phenomenon, tendency to keloid or hypertrophic scars. Coagulation disorders Other uncontrolled systemic diseases

Design outcomes

Primary

MeasureTime frame
Discoloration of vitiligo spots. Timepoint: Evaluation of lesions in both groups will continue every month until three months after the end of the interventions. Method of measurement: Discoloration of vitiligo patches will be graded as 1 (no response, milky white color still present, or erythematous color), 2 (opaque white color change), 3 (light brown color change), and 4 (normal skin color). Evaluation will also be done using the pigment score, which compares baseline vitiligo status and percent improvement as follows: 0, no response, 75%, excellent response.

Secondary

MeasureTime frame
Treatment complications. Timepoint: Evaluation of lesions in both groups will continue every month until three months after the end of the interventions. Method of measurement: Examination and history taking by the doctor.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyede Haleh Sadroleslami

Tabriz University of Medical Sciences

haleh.sadreslami@gmail.com+98 41 3335 7314

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026